Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 161 results found. Search for [ COVID19 vaccine trial ]

Results 1 to 21 of 161
BusinessToday.In
April 8, 2021
The COVID-19 sub-committee of WHO GACVS met on Wednesday to review the recent information from the British, EMA, and other medicines regulators


BusinessToday.In
April 7, 2021
Union Health Minister Harsh Vardhan noted that the sudden rise in coronavirus cases is largely or may be event-driven comprising local body elections, grand weddings, and farmers' protest


BusinessToday.In
April 5, 2021
Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients


BusinessToday.In
March 27, 2021
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax has announced final efficacy of 96.4 per cent against original COVID-19 virus. Novavax with Serum will provide 1.1 billion cumulative doses for COVAX Facility


BusinessToday.In
March 5, 2021
Covid-19 cases in some states like Maharashtra, Kerala, Punjab, Tamil Nadu, Gujarat and Karnataka are on the rise again. These states collectively account for 85.51 per cent of the new cases, as per the latest figures


BusinessToday.In
February 25, 2021
The real-world study involved around 1.2 million people in Israel. Pfizer vaccine has also proved to be effective against B.1.1.7 variant, also known as the UK variant of coronavirus


BusinessToday.In
February 9, 2021
WHO highlighted the need to reduce virus circulation and prevent infections so that it reduces the opportunities for coronavirus to mutate further.


Reuters
February 7, 2021
A study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant


BusinessToday.In
New Delhi, February 5, 2021
Pfizer Inc has withdrawn its application for emergency-use authorization of its COVID-19 vaccine in India that it had developed with Germany's BioNTech. The US company, which was the first drugmaker to apply for emergency use authorization of its coronavirus vaccine in India, had a meeting with the country's drugs regulator on Wednesday and the decision was made after that, the company said. India's Central Drugs Standard Control Organisation had declined to accept Pfizer's request for approval without a small local trial on the vaccine's safety and immunogenicity for Indians. Watch the video for more.Also Read: Pfizer withdraws emergency use application for COVID-19 vaccine in India


BusinessToday.In
January 30, 2021
Serum Institute of India CEO Adar Poonawalla said the company's tie-up with American vaccine developer Novavax has published 'excellent efficacy results'


BusinessToday.In
January 27, 2021
Coronvirus treatment: Plitidepsin, according to the researchers, should be considered for clinical trials based on its in vivo study results. Plitidepsin aka Aplidin is owned by Spanish pharmaceutical company Pharma Mar


BusinessToday.In
January 25, 2021
The batch of medicines being identified for treating patients include ivermectin, a drug used to treat livestock and people infested with parasitic worms


Manali
January 22, 2021
Discussing the future of healthcare post-COVID at the Business Today MindRush event on Friday, January 22 , a panel of distinguished experts shared their views on how the present crisis will shape the basics of healthcare in times to come


PTI
January 17, 2021
People adopting a \"wait and watch\" approach, lack of communication and glitches in CoWin app are the major reasons why only 53 per cent people got the COVID-19 shots on the first day in Delhi, experts said on Sunday


Rajeev Dubey | Vivek Punj
January 11, 2021
Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers


Joe C Mathew
January 11, 2021
World Health Organization (WHO) chief scientist, Dr. Soumya Swaminathan's comments come in the backdrop of several Indian vaccine makers and medical experts complaining about the confusing manner in which DCGI has granted emergency use approvals for COVID-19 vaccines in India


BusinessToday.In
January 5, 2021
Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial


Reuters
January 3, 2021
India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine


BusinessToday.In
December 30, 2020
This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use


Shailendra Shukla
New Delhi, December 25, 2020
51 lakh people in Delhi to receive coronavirus vaccine in phase-1 of vaccinationDelhi Chief Minister Arvind Kejriwal said that the capital is fully ready to receive, store and give coronavirus vaccine to \"priority category\" people in the first phase of vaccination. The CM said that he has identified 51 lakh people who will be the first ones to get vaccinated under the \"priority category\", which includes frontline workers, health workers, and people above 50 or having co-morbidities.Coro...


PAGES 1 OF 9  12345